When NCI-supported researchers discovered that the HER2 gene is important for breast cancer growth, this led to the development of the drug trastuzumab and other targeted treatments that have improved survival for women with HER2-positive breast cancer. For years, doctors and researchers have noted that not all cancers are alike. But for other patients, their tumors grow rapidly and spread like wildfire.
However, this page has some great information as well. These are all related terms because the presence of certain proteins is what makes a tumor more receptive to certain hormones. Some hormones affect growth rates, such as the hormones attracted by HER-2 proteins.
By Alice Goodman December 10, Advertisement. Recent studies have more clearly defined the role of pertuzumab Perjeta and neratinib Nerlynx. A question currently on the table is the optimal duration of trastuzumab.
Not all breast cancers are the same. Understand what type of breast cancer you have and how it differs from other types of breast cancer. Once you've been diagnosed with breast cancer, your doctor will review your pathology report and the results of any imaging tests to understand the specifics of your tumor. Using a tissue sample from your breast biopsy or using your tumor if you've already undergone surgery, your medical team determines your breast cancer type.
Surgery was associated with higher survival rates for patients with HER2-positive HER2 stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting Between 20 and 30 percent of all newly diagnosed stage 4 breast cancer cases are HER2explained the study's lead author, Ross Mudgway, a medical student at the University of California, Riverside School of Medicine. This form of breast cancer once had poor outcomes, but in recent years, advances in targeted therapy, such as trastuzumab Herceptinhave led to improved survival.
A number of clinical trials have determined the optimal combinations of HER2-targeting agents with cytotoxic therapies. In patients with HER2-positive metastatic breast cancer, HER2 therapies are usually given as part of an aggressive treatment approach involving a combination of trastuzumab and pertuzumab, as well as chemotherapy, usually taxanes or vinorelbine. The challenge is to identify which patients can be spared chemotherapy and its associated toxicities without losing the survival advantage.
As previously reported, the strategy does not worsen two-year overall survival but significantly shortens progression-free survival. The phase II trial randomly allocated patients to trastuzumab plus pertuzumab alone versus trastuzumab plus pertuzumab combined with chemotherapy until progression. After progression, both groups received T-DM1 as second line therapy.
The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic improvements in survival in both early and advanced settings. Despite this breakthrough, nearly all patients with metastatic HER2-positive breast cancer eventually progress on anti-HER2 therapy due to de novo or acquired resistance. A better understanding not only of the underlying mechanisms of HER2 therapy resistance but of tumor heterogeneity as well as the host and tumor microenvironment is essential for the development of new strategies to further improve patient outcomes.